CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma
In patients with melanoma, increased RAS/mitogen-activated protein kinase (MAPK) pathway activity is known to drive chemotherapy resistance. Here, the authors identify CDK12 as a downstream effector of the RAS/MAPK pathway and therapeutic target which mediates chemotherapy resistance through increas...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-10-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-022-34179-8 |
| _version_ | 1797991638076751872 |
|---|---|
| author | Thibault Houles Geneviève Lavoie Sami Nourreddine Winnie Cheung Éric Vaillancourt-Jean Célia M. Guérin Mathieu Bouttier Benoit Grondin Sichun Lin Marc K. Saba-El-Leil Stephane Angers Sylvain Meloche Philippe P. Roux |
| author_facet | Thibault Houles Geneviève Lavoie Sami Nourreddine Winnie Cheung Éric Vaillancourt-Jean Célia M. Guérin Mathieu Bouttier Benoit Grondin Sichun Lin Marc K. Saba-El-Leil Stephane Angers Sylvain Meloche Philippe P. Roux |
| author_sort | Thibault Houles |
| collection | DOAJ |
| description | In patients with melanoma, increased RAS/mitogen-activated protein kinase (MAPK) pathway activity is known to drive chemotherapy resistance. Here, the authors identify CDK12 as a downstream effector of the RAS/MAPK pathway and therapeutic target which mediates chemotherapy resistance through increased expression of DNA repair associated genes. |
| first_indexed | 2024-04-11T08:54:06Z |
| format | Article |
| id | doaj.art-875e347a38ed42f697dc3427cce904d4 |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-04-11T08:54:06Z |
| publishDate | 2022-10-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-875e347a38ed42f697dc3427cce904d42022-12-22T04:33:20ZengNature PortfolioNature Communications2041-17232022-10-0113111610.1038/s41467-022-34179-8CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanomaThibault Houles0Geneviève Lavoie1Sami Nourreddine2Winnie Cheung3Éric Vaillancourt-Jean4Célia M. Guérin5Mathieu Bouttier6Benoit Grondin7Sichun Lin8Marc K. Saba-El-Leil9Stephane Angers10Sylvain Meloche11Philippe P. Roux12Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, 2950, Chemin de la PolytechniqueInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, 2950, Chemin de la PolytechniqueInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, 2950, Chemin de la PolytechniqueInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, 2950, Chemin de la PolytechniqueInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, 2950, Chemin de la PolytechniqueInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, 2950, Chemin de la PolytechniqueInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, 2950, Chemin de la PolytechniqueInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, 2950, Chemin de la PolytechniqueDonnelly Centre for Cellular & Biomolecular Research, Temerty Faculty of Medicine, University of TorontoInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, 2950, Chemin de la PolytechniqueDonnelly Centre for Cellular & Biomolecular Research, Temerty Faculty of Medicine, University of TorontoInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, 2950, Chemin de la PolytechniqueInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, 2950, Chemin de la PolytechniqueIn patients with melanoma, increased RAS/mitogen-activated protein kinase (MAPK) pathway activity is known to drive chemotherapy resistance. Here, the authors identify CDK12 as a downstream effector of the RAS/MAPK pathway and therapeutic target which mediates chemotherapy resistance through increased expression of DNA repair associated genes.https://doi.org/10.1038/s41467-022-34179-8 |
| spellingShingle | Thibault Houles Geneviève Lavoie Sami Nourreddine Winnie Cheung Éric Vaillancourt-Jean Célia M. Guérin Mathieu Bouttier Benoit Grondin Sichun Lin Marc K. Saba-El-Leil Stephane Angers Sylvain Meloche Philippe P. Roux CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma Nature Communications |
| title | CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma |
| title_full | CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma |
| title_fullStr | CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma |
| title_full_unstemmed | CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma |
| title_short | CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma |
| title_sort | cdk12 is hyperactivated and a synthetic lethal target in braf mutated melanoma |
| url | https://doi.org/10.1038/s41467-022-34179-8 |
| work_keys_str_mv | AT thibaulthoules cdk12ishyperactivatedandasyntheticlethaltargetinbrafmutatedmelanoma AT genevievelavoie cdk12ishyperactivatedandasyntheticlethaltargetinbrafmutatedmelanoma AT saminourreddine cdk12ishyperactivatedandasyntheticlethaltargetinbrafmutatedmelanoma AT winniecheung cdk12ishyperactivatedandasyntheticlethaltargetinbrafmutatedmelanoma AT ericvaillancourtjean cdk12ishyperactivatedandasyntheticlethaltargetinbrafmutatedmelanoma AT celiamguerin cdk12ishyperactivatedandasyntheticlethaltargetinbrafmutatedmelanoma AT mathieubouttier cdk12ishyperactivatedandasyntheticlethaltargetinbrafmutatedmelanoma AT benoitgrondin cdk12ishyperactivatedandasyntheticlethaltargetinbrafmutatedmelanoma AT sichunlin cdk12ishyperactivatedandasyntheticlethaltargetinbrafmutatedmelanoma AT marcksabaelleil cdk12ishyperactivatedandasyntheticlethaltargetinbrafmutatedmelanoma AT stephaneangers cdk12ishyperactivatedandasyntheticlethaltargetinbrafmutatedmelanoma AT sylvainmeloche cdk12ishyperactivatedandasyntheticlethaltargetinbrafmutatedmelanoma AT philippeproux cdk12ishyperactivatedandasyntheticlethaltargetinbrafmutatedmelanoma |